280 related articles for article (PubMed ID: 32710930)
1. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.
Ciardiello D; Elez E; Tabernero J; Seoane J
Ann Oncol; 2020 Oct; 31(10):1336-1349. PubMed ID: 32710930
[TBL] [Abstract][Full Text] [Related]
2. TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity.
Ali S; Rehman MU; Yatoo AM; Arafah A; Khan A; Rashid S; Majid S; Ali A; Ali MN
Eur J Pharmacol; 2023 May; 947():175678. PubMed ID: 36990262
[TBL] [Abstract][Full Text] [Related]
3. TGFβ Signaling in the Tumor Microenvironment.
Goulet CR; Pouliot F
Adv Exp Med Biol; 2021; 1270():89-105. PubMed ID: 33123995
[TBL] [Abstract][Full Text] [Related]
4. Targeting the TGFβ pathway for cancer therapy.
Neuzillet C; Tijeras-Raballand A; Cohen R; Cros J; Faivre S; Raymond E; de Gramont A
Pharmacol Ther; 2015 Mar; 147():22-31. PubMed ID: 25444759
[TBL] [Abstract][Full Text] [Related]
5. TGFβ signaling activation correlates with immune-inflamed tumor microenvironment across human cancers and predicts response to immunotherapy.
Xia J; Zhang Q; Luan J; Min P; Zhang H; Chen G; Ji C; Song N
Cell Cycle; 2023 Jan; 22(1):57-72. PubMed ID: 35923142
[TBL] [Abstract][Full Text] [Related]
6. The TGFBeta pathway as a therapeutic target in cancer.
Seoane J
Clin Transl Oncol; 2008 Jan; 10(1):14-9. PubMed ID: 18208788
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?
Tan AR; Alexe G; Reiss M
Breast Cancer Res Treat; 2009 Jun; 115(3):453-95. PubMed ID: 18841463
[TBL] [Abstract][Full Text] [Related]
8. Overcoming TGFβ-mediated immune evasion in cancer.
Tauriello DVF; Sancho E; Batlle E
Nat Rev Cancer; 2022 Jan; 22(1):25-44. PubMed ID: 34671117
[TBL] [Abstract][Full Text] [Related]
9. Novel therapies emerging in oncology to target the TGF-β pathway.
Kim BG; Malek E; Choi SH; Ignatz-Hoover JJ; Driscoll JJ
J Hematol Oncol; 2021 Apr; 14(1):55. PubMed ID: 33823905
[TBL] [Abstract][Full Text] [Related]
10. TGF beta inhibition for cancer therapy.
Saunier EF; Akhurst RJ
Curr Cancer Drug Targets; 2006 Nov; 6(7):565-78. PubMed ID: 17100564
[TBL] [Abstract][Full Text] [Related]
11. The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial.
Metropulos AE; Munshi HG; Principe DR
EBioMedicine; 2022 Dec; 86():104380. PubMed ID: 36455409
[TBL] [Abstract][Full Text] [Related]
12. Exploiting Canonical TGFβ Signaling in Cancer Treatment.
Liu Q; Chen G; Moore J; Guix I; Placantonakis D; Barcellos-Hoff MH
Mol Cancer Ther; 2022 Jan; 21(1):16-24. PubMed ID: 34670783
[TBL] [Abstract][Full Text] [Related]
13. Targeting TGFβ signal transduction for cancer therapy.
Liu S; Ren J; Ten Dijke P
Signal Transduct Target Ther; 2021 Jan; 6(1):8. PubMed ID: 33414388
[TBL] [Abstract][Full Text] [Related]
14. TGFβ: Signaling Blockade for Cancer Immunotherapy.
Chen SY; Mamai O; Akhurst RJ
Annu Rev Cancer Biol; 2022; 6(1):123-146. PubMed ID: 36382146
[TBL] [Abstract][Full Text] [Related]
15. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
[TBL] [Abstract][Full Text] [Related]
16. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.
Ravi R; Noonan KA; Pham V; Bedi R; Zhavoronkov A; Ozerov IV; Makarev E; V Artemov A; Wysocki PT; Mehra R; Nimmagadda S; Marchionni L; Sidransky D; Borrello IM; Izumchenko E; Bedi A
Nat Commun; 2018 Feb; 9(1):741. PubMed ID: 29467463
[TBL] [Abstract][Full Text] [Related]
17. Targeting TGFbeta signaling for cancer therapy.
Iyer S; Wang ZG; Akhtari M; Zhao W; Seth P
Cancer Biol Ther; 2005 Mar; 4(3):261-6. PubMed ID: 15846079
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response.
Hanks BA; Morse MA
Curr Opin Investig Drugs; 2010 Dec; 11(12):1342-53. PubMed ID: 21154116
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy.
Barcellos-Hoff MH; Gulley JL
Clin Cancer Res; 2023 Jun; 29(11):2025-2033. PubMed ID: 36598437
[TBL] [Abstract][Full Text] [Related]
20. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
